18 October 2024
Freshfields advises Zentiva on public purchase offer for Apontis Pharma
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Stephanie Hundertmark Lead | Freshfields | Partner | Corporate/M&A | Berlin |
| Sabrina Kulenkamp Lead | Freshfields | Partner | Corporate/M&A | Not stated |
| Thomas Kelm | Freshfields | Associate | Corporate/M&A | Frankfurt |
| Antonius Gehringhoff | Freshfields | Associate | Corporate/M&A | Berlin |
| Burak Firat | Freshfields | Associate | Corporate/M&A | Berlin |
| Rebecca Hettich | Freshfields | Associate | Corporate/M&A | Frankfurt |
| Frank Röhling | Freshfields | Partner | Antitrust | Berlin |
| Bertrand Guerin | Freshfields | Counsel | Antitrust | Berlin |
| Mariusz Motyka-Mojkowski | Freshfields | Counsel | Antitrust | Berlin |
| Lasse Petersen | Freshfields | Other | Antitrust | Berlin |
| Celia Diederichs | Freshfields | Associate | Antitrust | Berlin |
| Philipp Lehmann | Freshfields | Counsel | Commercial | Hamburg |
| Zahar Qasim | Freshfields | Associate | Commercial | Hamburg |
| Flavia Lang | Freshfields | Other | Employment | Hamburg |
11 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- EUR 10 (€10.00 per share)
- What the figure measures
- Per share
- Client
- ZentivaBuy-side
- Counterparties
- Apontis Pharma AG (Target)
Paragon (Sell-side)